Status:

ACTIVE_NOT_RECRUITING

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Genital Warts

Eligibility:

MALE

9-19 years

Phase:

PHASE3

Brief Summary

This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 d...

Eligibility Criteria

Inclusion

  • Is a healthy Chinese male.
  • Has not had sexual debut at the time of enrollment, and does not plan on becoming sexually active during the vaccination period (Day 1 through one month post last dose).

Exclusion

  • Has a history of known prior vaccination with an HPV vaccine.
  • Has a history of HPV-related external genital lesions, HPV-related intra-anal lesions, or HPV-related head and neck cancer.
  • Has a history of severe allergic reaction that required medical intervention.
  • Has received immune globulin or blood-derived products in the past 6 months or plans to receive any before one month post last dose.
  • Has a history of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, human immunodeficiency virus (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
  • Has received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids and certain regimens of systemic corticosteroids.
  • Has a known thrombocytopenia or coagulation disorder that would contraindicate IM injections.

Key Trial Info

Start Date :

May 7 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 19 2029

Estimated Enrollment :

1590 Patients enrolled

Trial Details

Trial ID

NCT05314023

Start Date

May 7 2022

End Date

February 19 2029

Last Update

January 19 2023

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Liucheng County Centers for Disease Control and Prevention ( Site 0005)

Liuchow, Guangxi, China, 545200

2

Center for Disease Control and Prevention of Rong An ( Site 0006)

Liuchow, Guangxi, China, 545400

3

Loudi Public Health Hospital (Loudi Occupational Disease Prevention And Treatment Hospital) ( Site 0

Louxing District, Hunan, China, 417000

4

Yuechi Disease Prevention and Control Center ( Site 0002)

Guang’an, Sichuan, China, 638399